What should I know about Boehringer Ingelheim?
Boehringer Ingelheim is a German pharmaceutical company headquartered in Ingelheim am Rhein. Albert Boehringer founded it in 1885, and it is fully owned by the Boehringer, Liebrecht and von Baumbach families. It has three main businesses: human pharmaceuticals, animal health and biopharmaceuticals (contract manufacturing for other drug companies). It employs about 54,300 people in 76 countries. According to the same source, its revenue was €27.8 billion in 2025, and it was the largest privately owned pharmaceutical company as of 2018.
What are Boehringer Ingelheim's main drugs?
Boehringer's best-known medicines are Jardiance, for type 2 diabetes, heart failure and kidney disease, Ofev, for lung disease, Spiriva, for respiratory conditions, and Pradaxa, a blood thinner. In July 2026 the company reported that first-half 2026 sales growth was driven by Jardiance and new product launches in the US. It invests roughly 28% of human pharma revenue in research and development. Jardiance is developed together with Eli Lilly.
What is Boehringer Ingelheim currently developing?
Boehringer's obesity candidate survodutide, which targets two hormone receptors, had a Phase 3 trial (SYNCHRONIZE-1) reported on 28 April 2026 that met its co-primary endpoints, with 16.6% weight loss. It is also being studied for liver disease. The company's 2025 pipeline included zongertinib, for HER2-mutated lung cancer, and nerandomilast, for the lung disease idiopathic pulmonary fibrosis, both awaiting FDA decisions at that time. Boehringer said it could launch up to 20 indications in the coming years.
Have there been any controversies involving Boehringer Ingelheim?
Boehringer's main legal controversy involved Pradaxa. In May 2014 it agreed to pay $650 million to settle about 4,000 US lawsuits alleging the blood thinner caused uncontrolled bleeding, which plaintiffs linked to more than 500 deaths. Boehringer denied wrongdoing. It said the FDA had reaffirmed the drug's positive benefit-risk profile and that settling let it avoid the uncertainty and distraction of prolonged litigation.
Is Boehringer Ingelheim publicly traded, and how big is it?
No. Boehringer Ingelheim is a private company, fully owned by three founding families, so it has no stock market listing, share price or market value. It does publish results. Its revenue was reported as €27.8 billion in 2025, which places it among the world's largest pharmaceutical companies. In July 2026 it said that first-half sales rose. It employs about 54,300 people.